Evidence map›Paper›PMID 35470161›Full record

ArticleAnnals of the rheumatic diseases2022

Auxilin is a novel susceptibility gene for congenital heart block which directly impacts fetal heart function.

Sabrina Meisgen, Malin Hedlund, Aurelie Ambrosi, Lasse Folkersen, Vijole Ottosson, David Forsberg, Gudny Ella Thorlacius, Luca Biavati, Linn Strandberg, Johannes Mofors and 18 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 5 countries.

Sabrina MeisgenDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Malin HedlundDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Aurelie AmbrosiDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Lasse FolkersenDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Vijole OttossonDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
David ForsbergDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Gudny Ella ThorlaciusDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Luca BiavatiDepartment of Physiology and Experimental Medicine, Hospital for Sick Children, Washington, DC, USA.
Linn StrandbergDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Johannes MoforsDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Daniel RamskoldDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Sabrina RuhrmannDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Lauro MeneghelDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
William NybergDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Alexander EspinosaDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Robert Murray HamiltonPediatric Cardiology, Hospital for Sick Children, Toronto, Ontario, Canada.
Anders Franco-CerecedaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Anders HamstenDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Tomas OlssonDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Lois GreeneNational Institutes of Health, Bethesda, Maryland, USA.
Per ErikssonDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Kristina Gemzell-DanielssonDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Stina SalomonssonDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Vijay K KuchrooEvergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts, USA.
Eric HerleniusDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Ingrid KockumDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Sven-Erik SonessonDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Marie Wahren-HerleniusDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden marie.wahren@ki.se.ORCID http://orcid.org/0000-0002-0915-7245
Karolinska University Hospital · SEKarolinska Institutet · SEHarvard University · USHospital for Sick Children · CANational Institutes of Health · US

Funding

Role of molecular chaperones in protein folding diseasesZIAHL000516 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI GREENE, LOIS · 2009 to 2022
$19.6M
6 · The paper itself

Abstract

objectiveNeonatal lupus erythematosus (NLE) may develop after transplacental transfer of maternal autoantibodies with cardiac manifestations (congenital heart block, CHB) including atrioventricular block, atrial and ventricular arrhythmias, and cardiomyopathies. The association with anti-Ro/SSA antibodies is well established, but a recurrence rate of only 12%-16% despite persisting maternal autoantibodies suggests that additional factors are required for CHB development. Here, we identify fetal genetic variants conferring risk of CHB and elucidate their effects on cardiac function.

methodsA genome-wide association study was performed in families with at least one case of CHB. Gene expression was analysed by microarrays, RNA sequencing and PCR and protein expression by western blot, immunohistochemistry, immunofluorescence and flow cytometry. Calcium regulation and connectivity were analysed in primary cardiomyocytes and cells induced from pleuripotent stem cells. Fetal heart performance was analysed by Doppler/echocardiography.

resultsWe identified

conclusionsOur study identifies auxilin as the first genetic susceptibility factor in NLE modulating cardiac function, opening new avenues for the development of screening and therapeutic strategies in CHB.

Indexed as

Atrioventricular BlockAuxilinsAnimalsAntibodies, AntinuclearAutoantibodiesFetal HeartGenome-Wide Association StudyHeart BlockLupus Erythematosus, SystemicMiceAntibodies, AntinuclearAutoantibodiesAuxilinsautoantibodiesautoimmunitypolymorphism, Geneticsjogren's syndrome

Identifiers

PMID35470161
PMCPMC9279836
OpenAlexW4224937817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.